SELECTA-GROUP
16.3.2022 15:24:07 CET | Business Wire | Press release
Q4 2021 performance summary1
Sales2 of €286.3 million, representing an increase of 15.7% compared to the Group’s sales for Q4 2020, was the highest sales quarter in the year. Despite restrictions due to new COVID variants, the Group continued to see activity gradually picking up reaching 79% of Q4 2019 Group’s sales.
Four key markets (France, UK and Ireland, Spain and Italy), which were the most affected by the pandemic, due to the impact of working from home policies in the Private segment and client attrition, saw a strong sales increase year on year. Other countries’ sales performance showed a significantly narrowed gap in the quarter compared to 2019.
Group sales growth compared to last year driven by a strong increase in SMD in all segments, more than offsetting machine park reduction, with strongest performance seen in the Semi-Public and the Public segments:
- In the Private segment, sales improvement driven by both Services and Administration and Manufacturing and Logistics.
- In the Semi-Public segment, strong sales improvement was driven by Education, Healthcare and HoReCa with Retail slightly lagging.
- In the Public segment strong sales improvement driven by all business areas.
Group SMD recovered but not yet to pre-pandemic level mostly due to the remaining gap in the Private segment, whilst Semi-public and Public SMD, fully recovered to 2019 levels.
Adjusted EBITDA2,3 of €64.7 million, up €36.5 million and Adjusted EBITDA2,3 margin of 22.6%, up 11.2pp driven by strong cost savings whilst investing in commercial initiatives.
Reported EBITDA2,3 of €48.2 million and free cash flow of -€9 million have been impacted by one-offs due to a deeper rightsizing.
Liquidity headroom4 of €154.1 million, reflects a resilient liquidity position which was maintained ahead of noteholder plan due to strong cash discipline.
Full year 2021 performance summary1
Sales2 of €1,039.7 million, increased 3.2% compared to 2020 have been impacted by the pandemic throughout the year, reached 73% of 2019 Group’s sales.
Adjusted EBITDA2,3 of €199.3 million, up €114.1 million compared to 2020 and overachieving by €26 million the noteholder plan. Adjusted EBITDA2,3 margin of 19.2%, up 10.7pp compared to 2020 driven by strong cost savings whilst investing in commercial initiatives.
Reported EBITDA2,3 of €158.1 million and free cash flow of €15.7 million have been impacted by one-offs due to a deeper rightsizing.
Joe Plumeri, Executive Chairman, said:
"In 2021, we achieved significant progress in the execution of our One Selecta vision and strategy - accomplishing and overdelivering against our objectives for the year. We continue to focus on best-in-class sales and service, using technology like our world-class CRM and Power BI platforms to deliver innovative solutions that address our clients' underlying needs and optimizing service to our clients."
Christian Schmitz, Group Chief Executive Officer, said:
"As European countries begin removing their Covid restrictions, we remain convinced that Selecta has the solutions needed to address the needs of the post-Covid world. Our 24/7, flexible, scalable food & beverage options cater beautifully to the new hybrid working models in place across companies. Combined with our strong partnerships with the A-brands in food, beverages and machine technologies, we have the foundation in place for sustainable future growth."
- ENDS -
About Selecta Group
Headquartered in Switzerland since 1957, Selecta Group is a Foodtech company with a leading route based, self-service distribution network in Europe, offering innovative convenience food services and world-class quality coffee brands in the workplace and public spaces. Active in the food tech business we continuously push on new innovations and solutions, we serve premium coffee and beverages, snacks, and fresh meals to more than 10 million people in 16 countries across Europe every day. With an annual turnover of €1.2 billion in 2021, we owe our success to our c.7,000 highly skilled, dedicated, and passionate Selecta employees who are committed to creating millions of moments of joy for our clients and their consumers every day. Sustainability is an integral part of the way we do business, focused on the key areas in which we can make a positive difference. For more information, please visit www.selecta.com .
Cautionary Statement
We are providing this information voluntarily, and the material contained in this announcement is presented solely for information purposes and is not to be construed as providing investment advice. As such, it has no regard to the specific investment objectives, financial situation or particular needs of any recipient. No representation or warranty, either express or implied, is made as to, and no reliance should be placed on, the fairness, completeness, accuracy, correctness or reliability of the information contained herein or the assumptions upon which the information is based. It should not be regarded by recipients as a substitute for the exercise of their own judgment. Neither Selecta, nor any of its directors, officers, employees, affiliates, direct or indirect shareholders, advisors or agents accepts any liability for any direct, indirect, consequential or other loss or damage suffered by any person as a result of relying on all or any part of this announcementand any liability is expressly disclaimed.
Forward-Looking Statements
This press release includes “forward-looking statements” that involve risks, uncertainties and otherfactors, many of which are outside of Selecta’s control and could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Selecta’s plans, objectives, goals, future events, performance or other information that is not historical information. All statements other than statements of historical fact referred to in this press release are forward-looking statements. Forward-looking statements give Selecta’s or the Group’s current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Such forward-looking statements, as well as those included in any other material, are subject to known and unknown risks, uncertainties and assumptions about Selecta, its present and future business strategies, trends in its operating industry and the environment in which it will operate in the future, future capital expenditure and acquisitions. In light of these risks, uncertaintiesand assumptions, the events in the forward looking statements may not occur or Selecta’s or the Group’s actual results, performance or achievements might be materially different from the expected results, performance or achievements expressed or implied by such forward looking statements. None of Selecta, its affiliates or their respective directors, officers, employees, agents or advisers undertake to publicly update or revise forward- looking statements to reflect subsequentevents or circumstances after the date made, except as required by law.
1 At actual exchange rates. There is no material difference from constant currency rates
2 Sales: Revenue after payment of vending fees
3 Adjusted EBITDA: Earnings before Interest, Tax, Depreciation and Amortization and prior to one-off items (external and internal costs which are not related to the on-going business). Include the effects of IFRS 16
4 Cash at Bank of €52.2 million plus €101.9 million available RCF
Note: Full year 2019 figures have been adjusted for one-time impacts
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005691/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
